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A B S T R A C TPlatelet aggregometry assays are generally used for the analysis of platelet function but can also be adapted for
further research and therapy focused applications. This method describes the procedures for the preparation of
human platelet-rich plasma (PRP) and platelet-poor plasma (PPP) for the assessment of human platelet
aggregation induced by agonists such as platelet-activating factor (PAF), thrombin, collagen, adenosine
diphosphate (ADP), arachidonic acid, etc.
 This method can be applied in vitro to evaluate the aggregatory effects of these agonists and to assess the
antiaggregatory effects of several bioactive antiplatelet agents (compounds of natural or pharmacological
origin) in human PRP.
 This versatile method can be used in both basic and clinical research for the assessment of platelet aggregation
(a major cardiovascular risk factor), platelet agonists, and inhibitors, in physiological or pathological
conditions.
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Human platelets are crucially involved in both normal haemostasis, pathological bleeding, and
thrombosis. These platelets contribute greatly to vessel constriction and repair, host defence, and
when acting together with other cells (i.e. white blood cells, endothelial, or smooth muscle cells) they
also participate in inflammatory pathologies, such as the promotion of atherosclerosis, tumor growth,
and metastasis [2–6]. During the interaction between platelets and the vessel wall, at the site of
damage platelets are rapidly engaged in a sequence of functional responses including various steps in
platelet activation, adhesion, spreading, shape change, aggregation, release reaction, exposure of a
procoagulant surface, and clot retraction. These processes lead to the formation of a haemostatic plug
that occludes the site of injury to prevent blood loss. An increased risk of bleeding could be present
when the platelet count is reduced and/or one of their functions is defective. Conversely, improper
thrombus formation could be due to a growth in platelet count or reactivity. Activated platelets adhere
and aggregate within atherosclerotic lesions, forming occluding arterial thrombi that may result in
atherothrombotic manifestations such as stroke or myocardial infarction, two of the major causes of
morbidity and mortality in the Western world [2].
Several agonists of platelet activation and aggregation are implicated in all steps of these
pathologies, such as the platelet-activating factor (PAF) and thrombin. Antiplatelet compounds of
either natural, dietary or pharmacological origin have been found to beneficially reduce these effects
[2]. Thus, the European Food Safety Authority (EFSA) has accepted that decreasing platelet aggregation
in subjects with platelet activation during sustained exposure to a food or food constituent over four
weeks is a beneficial physiological effect [7]. A food constituent that demonstrates these properties
can be granted a valid health claim from EFSA [8]. Therefore, reliable platelet functions tests are
required to assess such a wide range of functions, effects of platelet aggregatory agonists, and
antiplatelet compounds. The revolutionary platelet aggregation test in platelet-rich plasma (PRP),
called light transmission aggregometry (LTA), was developed by Born [9] and O’Brien [10] in the 1960s.
LTA is considered the gold standard for testing platelet function and it is still in use for evaluating and
monitoring platelet defects and the effects of platelet aggregation agonists and antiplatelet
compounds.
LTA measures the transmission of light through a sample of platelets in suspension (PRP, washed
platelets or gel-filtered platelets), which increases when platelets are aggregated by an agonist such as
PAF, thrombin, ADP, arachidonic acid (AA), collagen, epinephrine (EPI), etc. (Fig. 1A). LTA is a time-
consuming and technically challenging technique that is affected by many preanalytical and analytical
variables, thus it must be carefully controlled and performed by expert personnel in specialised
laboratories [11].
The method outlined in this manuscript describes the processing required to prepare human PRP
and PPP and the analytical procedures required to assess platelet aggregation of PRP induced by
agonists such as PAF and thrombin using LTA in vitro. Previous research relating to antiplatelet
compounds or antithrombotic food constituents focused on the use of washed rabbit platelets or
rabbit PRP [12–19]. This method describes the assessment of these antiplatelet compounds using
Fig. 1. Application of LTA assay for evaluating and monitoring the effect of several agonists (i.e. PAF or thrombin) on platelet
aggregation of PRP. (A): Detection of increased light transmission during platelet aggregation; baseline light transmission is
acquired when platelets of PRP suspensions are in an aggregometer cuvette in the absence of an agonist. Increased light
transmission is detected when platelets start to aggregate in the presence of an agonist in the aggregometer cuvette leading to
the development of an aggregation curve. (B): Characteristic examples of an aggregation curve of a maximum irreversible
platelet aggregation [B1: Trace 1 (blue)] and of an aggregation curve of a maximum-reversible platelet aggregation [B2: trace 2
(black)]. The latent aggregation curve (B2) of maximum-reversible platelet aggregation of hPRP induced by an agonist (PAF or
thrombin) is determined as the 100% aggregation of platelets. (C): The addition of several concentrations of an agonist (PAF or
thrombin) within a specific range can induce reversible platelet aggregation in a concentration dependent manner; i.e. the
higher the concentration of the agonist (C5 > C4 > C3 > C2 > C1) the higher the platelet aggregation curve (E > D > C > B > A) that
is obtained by the aggregometer detector of the LTA assay. (D): A linear relationship exists between the concentrations of an
agonist (i.e. PAF or thrombin) within a specific range that induces platelet aggregation within the 20%–80% of the maximum-
reversible platelet aggregation of hPRP. From this linear curve the concentration of the agonist needed to induce 50% of platelet
aggregation can be calculated, which is known as the EC50 value of the specific agonist for platelet aggregation. The lower the
EC50 value for an agonist the higher the potency of its platelet aggregation effect. All experiments must be performed in
triplicate (n = 3), using a different donor’s blood sample for each replicate, to ensure reproducibility. Abbreviations: LTA: light
transmission aggregometry; PAF: platelet-activating factor; hPRP: human platelet-rich plasma.
A. Tsoupras et al. / MethodsX 6 (2019) 63–70 65human PRP in vitro [1]. This is important for preclinical evaluation of the health benefits or side-effects
of these antiplatelet compounds on platelet function and cardiovascular health before the use of these
compounds in in vivo, ex vivo, or clinical research.
Materials, methods and applications
Materials and reagents
All plastic consumables, reagents, and solvents were of analytical grade and were purchased from
Fisher Scientific Ltd. (Dublin, Ireland). 20 gauge (G) safety needles and evacuated sodium citrate S-
monovettes1 for blood sampling were purchased from Sarstedt Ltd. (Wexford, Ireland). Bioassays on
human PRP (hPRP) were carried out on a Chrono-log-490 two channel turbidimetric platelet
aggregometer (Havertown, PA, USA), coupled to the accompanying AGGRO/LINK software package. All
platelet aggregation consumables were purchased from Labmedics LLP (Abingdon on Thames, UK).
Standard PAF, thrombin and bovine serum albumin (BSA) were purchased from Sigma Aldrich
(Wicklow, Ireland). Centrifugations were carried out on an Eppendorf 5702R centrifuge (Eppendorf
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photometer (Kyoto, Japan).
Preparation of PAF
PAF is purchased as a crystalline substance (Sigma Aldrich, Wicklow, Ireland). Dilute the PAF in an
appropriate amount of a chloroform/methanol (1:1 v/v) solution so that the stock concentration is
104 M, which should then be aliquoted for storage at 20 C. When ready for use, the aliquoted stock
solutions should be evaporated under a stream of nitrogen and re-dissolved in BSA-saline (2.5 mg BSA/
mL 0.9% saline). This should then be serially diluted in BSA-saline to obtain solutions of PAF dissolved
in BSA-saline with a final concentration in the cuvette ranging from 2.6  108 to 2.6  105 mol/L.
Preparation of thrombin
Crystalline standard active thrombin (Sigma Aldrich, Wicklow, Ireland) should be dissolved in
saline, so that the stock concentration is 0.1 U/mL and this solution can be aliquoted for storage at
80 C. When ready for use, the aliquoted stock solutions should be diluted in appropriate amounts of
saline to obtain solutions of thrombin with a final concentration in the aggregometer cuvette ranging
from 0.01mU/mL to 1mU/mL.
Preparation of platelet-rich plasma (PRP) and platelet-poor plasma (PPP)
Blood withdrawal and the preparation and processing of human PRP can be performed as
previously described [1] and outlined in detail below:1 For PRP isolation, volunteers donate fasting blood samples (for at least 8 h).
2 Blood should collected from the median cubital vein or cephalic vein of healthy volunteers via
venepuncture using a 20 G safety needle. Blood must be drawn into sodium citrate anticoagulant S-
monovettes (0.106 mol/L in a 1:10 ratio of citrate to blood; Sarstedt Ltd., Wexford, Ireland) using the
aspiration method (or similar collection systems and venepuncture methods). The monovette must
be gently inverted three times to ensure effective mixing of the anticoagulant.3 The collected blood samples should then centrifuged at 194 x g for 18 min at 24 C with no brake
applied to prevent any platelet activation. The supernatant PRP must then gently transferred to
polypropylene tubes using a polypropylene Pasteur pipette and the PRP is stored at 24 C.4 The PPP is obtained by further centrifuging the remainder of the PRP specimen in the monovette at
1465 x g for 20 min at 24 C, again with no brake applied.5 PRP can be adjusted to 500,000 platelets/mL if required by addition of a respective volume of PPP
according to the absorbance of the PRP measured. The absorbance is measured using a
spectrophotometer set at 530 nm and the PPP is used as a blank. 1 mL of PPP and PRP are placed
in plastic cuvettes and the absorbance is measured. An absorbance of 0.8 is equivalent to 500,000
platelets/mL.6 All procedures should take place at 24 C and should be carried out within 2.5 h of the initial blood
draw for optimum performance.
Notes on the preparation of human platelet-rich plasma
 Ensure to use a wide bore needle for blood withdrawal if the one recommended in this protocol is
not available to prevent unnecessary platelet aggregation or activation. Ensure that the monovettes or similar collection tubes are in date before use.
 Venepuncture should be clean without the requirement of probing for a vein, to avoid platelet
activation and haemolysis. Follow the local standard operating protocols for venepuncture. It is recommended that platelets are handled and stored in polypropylene, polyethylene or
polycarbonate labware. In addition, stored platelets should always be sealed with a cap to ensure
that the pH of the hPRP remains stable. Note that glass containers, vigorous movement of containers
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platelet function or premature platelet activation. Blood and intact platelets should preferentially be handled at room temperature (approximately
24 C). Note that platelets at 4 C can activate and suffer loss of function. Many pharmaceutical compounds and various reagents are known to interfere with platelet
function. Ensure that the potential donors have not used the following drugs two weeks prior to
blood draw: anti-histamines, antibiotics, aspirin, anaesthetics, dextran, PAF-inhibitors such as
Rupatadine or some herbal medicines, non-steroidal anti-inflammatory medication (Aspirin,
Clopidogrel, Cilostazol, Ibuprofen, Ticlopidine, Ticagrelor, Prasugrel – or any other vascular or
cardiovascular related medications). Some foods and beverages such as coffee, garlic, and wine can also impact platelet function. Ensure
that volunteers have been fasting for a minimum of 8 h prior to testing. The preparation of thrombin and PAF is described in this methodology, however, other agonists can
just as easily be applied to these methods.
Aggregometry protocols
Basic aggregometry protocol
The aim of this protocol is to describe basic aggregometry testing. However, consult the
manufacturer’s guidelines associated with the particular model of aggregometer and adjust this
method accordingly. The basic aggregometry protocol in human PRP can be performed as previously
described [1] with modification as outlined below:1 Draw and process the blood as described in section 2.4.
2 Prior to testing, add 250 mL of PPP to a glass aggregometer cuvette with a spacer attached (see note
below) without a stirrer and place it in the appropriate well in the aggregometer.3 Then pipette 250 mL of hPRP into another glass cuvette, which is placed in a Chrono-log-490 two
channel turbidimetric platelet aggregometer (Havertown, PA, USA), coupled to the accompanying
AGGRO/LINK software package. This is a Born type aggregometer with a fixed wave
spectrophotometer and a sample chamber where the cuvette filled with PRP is placed at 37 C.
Add a small disposable stirrer to the cuvette spinning at 1200 rpm and allow the cuvette to prewarm
before testing. This allows assay to mimic the in vivo conditions of blood flow.4 Then, automatically calibrate (zero) the PRP against the PPP (follow the manufacturer’s
instructions). In doing so, the instrument is set to 100% transmission and then 0% transmission
in order to gauge the possible parameters. When complete, wait 30 s to establish a stable baseline,
prior to the addition of any agonists.5 Baseline light transmission is obtained when platelets of hPRP suspensions are in an aggregometer
cuvette in the absence of an agonist, while increased light transmission is detected when platelets
start to aggregate in the presence of an agonist in the aggregometer cuvette (Fig. 1A). According to
the detection of these changes of the light transmission specific aggregation curves are acquired. A
characteristic example of an aggregation curve of a maximum-irreversible platelet aggregation is
shown in Fig. 1(B1), while a characteristic example of an aggregation curve of a maximum-
reversible platelet aggregation is shown in Fig. 1(B2).6 The latent aggregationcurve (Fig.1B2) of maximum-reversible plateletaggregationof hPRPinducedby
an agonist (PAForthrombin) isdetermined asthe 100% aggregationof platelets. Thisaggregationcurve
is very important to determine in each PRP sample in order to carryout some of the applications of LTA,
including the evaluation of the effects of platelet agonists and antiplatelet compounds.
Notes on the Aggregometry Protocol: Use pipette tips with a wide orifice to prevent damage or activation of the platelets.
 Ensure that the PRP is pipetted directly into the centre of the cuvette to prevent activation of the
platelets by the glass cuvettes.
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or bubble formation. Wear gloves when handling clinical material for personal protection, but also to prevent any
smudges or fingerprints that may affect the aggregometer analysing the contents of the glass
cuvettes. Clean and inspect all cuvettes before use with a lint free disposable tissue. Dispose of all clinical waste and sharps correctly according following local standard operating
procedures. The Chrono-log cuvettes can be fitted with a spacer. This is a small rubber object placed underneath
the cuvette to raise the height of the cuvette. Ordinarily, 500 mL of PRP would be required to test in
the Chrono-log aggregometer. However, spacers allow for a lower volume of PRP to be used. Some aggregometer stirrers are set at 1000 RPM as opposed to 1200 RPM, which is satisfactory.
Application of LTA for the evaluation of platelet agonists on platelet aggregation of PRP (EC50 values)
The application of LTA for evaluating the effects of agonists (i.e. PAF or thrombin) on platelet
aggregation of PRP can be achieved as previously described [20], with some modifications. Briefly:1 Blood collection and processing should be conducted as described in section 2.4, followed by the
basic aggregometry protocol and the LTA assay (section 2.5.1).2 Several PRP suspensions should be prepared in aggregometer cuvettes, and the aggregation curve of
maximum-reversible platelet aggregation of hPRP induced by an agonist (PAF or thrombin) must be
determined and characterised as 100% aggregation of platelets (Fig. 1B1).3 Several concentrations of agonist (within a specific range) should be added to the aggregometer
cuvette, which can induce reversible platelet aggregation in a concentration dependent manner
(Fig. 1C). The higher the concentration of the agonist the higher the platelet aggregation curve
detected by the aggregometer (Fig. 1C).4 A linear relationship exists between the concentrations of an agonist (i.e. PAF or thrombin) within a
specific range that induces platelet aggregation within the 20%–80% of the maximum-reversible
platelet aggregation of hPRP. From this linear curve the concentration of the agonist require to
induce 50% of platelet aggregation can be calculated, which is termed the EC50 value (half maximal
effective concentration) of the specific agonist for platelet aggregation (Fig. 1D). The lower the EC50
value for an agonist the higher the potency of its platelet aggregation effect.
LTA for the evaluation of the inhibitory effects (IC50 values) of an antiplatelet agent against platelet
aggregation of PRP
The application of LTA for evaluating the inhibitory effects of an antiplatelet agent either of natural,
dietary or pharmacological origin against platelet aggregation of PRP induced by PAF or thrombin can
be achieved as previously described [12–18,21,22], with some modifications as previously described
[1]. Briefly:1 Blood collection and processing should be conducted as described section in 2.4, followed by the
basic aggregometry protocol (Section 2.5.1) and the LTA assay (Section 2.5.2).2 The aggregation curve of the maximum-reversible platelet aggregation of PRP (100% aggregation of
platelets) induced by a specific concentration of an agonist (PAF or thrombin) in the absence of any
antiplatelet agent is determined as the 0% inhibition (baseline).3 Platelet suspensions of PRP are incubated in the presence of several concentrations of the
antiplatelet compound for 2 min with stirring prior to the addition of any agonist.4 By the addition of the same concentration of the agonist that was used for the baseline aggregation
curve (100% of aggregation - 0% of inhibition) to the preincubated PRP cuvettes containing antiplatelet
agent PRP suspensions, a reduction of the platelet aggregation curve should be observed (inhibitory
effect) in relation to the baseline aggregation curve in a concentration dependent manner.5 Generally, the higher the concentration of the antiplatelet agent in the aggregometer cuvette, the
lower the platelet aggregation curve recorded by the aggregometer detector of the LTA assay,
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inhibition in relation to the baseline aggregation curve (0% inhibition – 100% aggregation).6 A linear relationship exists between the concentrations of the antiplatelet agent within a specific
range that inhibits platelet aggregation within the 20%–80% of the maximum-reversible platelet
aggregation of hPRP. From this linear curve the concentration of the agonist needed to achieve 50%
inhibition of platelet aggregation can be calculated, which is known as the half maximal inhibitory
concentration (IC50) value for the specific antiplatelet agent against platelet aggregation. The IC50
values reflect the inhibitory strength of each antiplatelet agent. The lower the IC50 value for an
antiplatelet agent the higher its inhibitory effect against platelet aggregation induced by an agonist
such as PAF or thrombin.
Notes on assessing the inhibitory effects of potential antiaggregatory compounds:
 The application of LTA for evaluating the inhibitory effects (IC50 values) of an antiplatelet agent
against platelet aggregation of PRP induced by PAF or thrombin is important, since it provides
information concerning the pathway that this antiplatelet compound can affect or inhibit (either
that of the PAF/PAF-receptor pathway or that of the Thrombin/PAR-1 pathway, or both), and at which
concentration these effects are induced [1,12–14,16–19]. These in vitro results are crucial for
determining further research, either in cells and cell-related responses in vitro or ex vivo/in vivo in
humans/animal-models. Suitable controls can be used before conducting the in vitro studies by using a known antagonist of
the platelet agonist. For instance if testing with PAF and/or PAF-like molecules with agonistic effect
[2], pharmacological inhibitors such as Rupatadine or CV-3988 may be used, or inhibitors of natural
origin such as Ginkgolide B (i.e. BN52021) to assess and compare to the antiplatelet agent being
tested as previously described [23,24].
Conclusions
The methods and protocols described in this article can be applied as a tool for research in a basic
and clinical setting by clinical researchers, biochemists, food and nutrition scientists and related
laboratories who wish to assess platelet function and the effects of antiplatelet bioactive compounds
on platelet aggregation induced by potent agonists such as PAF or thrombin using LTA. Relevant
applications of the LTA assay and related methods and protocols described in this manuscript, can
provide information about the health benefits or side-effects of various compounds on platelet
function and cardiovascular health.
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